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 ABSTRACT 
Although being a primary objective in the management of type 2 diabetes, optimal 
glycaemic control is difficult to achieve and usually not maintained over time. Type 2 
diabetes is a complex pathology, comprising altered insulin sensitivity and impaired 
insulin secretion. Recent advances in the understanding of the physiological functions of 
incretins and their degrading enzyme dipeptidyl-peptidase (DPP)-4 have led to the 
‘discovery’ of a new class of oral anti-diabetic drugs. Several DPP-4 inhibitors (or 
gliptins) with different chemical structures are now available. These agents inhibit the 
degradation of the incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP) and hence potentiate glucose-dependent insulin 
secretion. DPP-4 inhibitors inhibit DPP-4 activity by almost 100% in vitro, maintaining a 
>80% inhibition throughout the treatment period in vivo, thus prolonging GLP-1 half-life, 
and significantly reducing HbA1c generally by -0.7 – 0.8% as well as fasting and post-
prandial glycaemia. They are well-tolerated with no weight gain and few adverse effects, 
and, of particular interest, no increase in hypoglycaemic episodes. Although different by 
their chemical structure and pharmacokinetic properties, the DPP4 inhibitors currently 
available have proven similar glucose lowering efficacy. 
 
 
 
 
INTRODUCTION 
Diabetes mellitus is recognized as a major health problem affecting millions of people 
and predisposing to micro- and macro-vascular complications including coronary heart 
disease. A tight glycaemic control reduces the morbidity and mortality associated to type 
2 diabetes [1;2], but has proven challenging and is usually not sustained. The currently 
used anti-diabetic drugs show a loss of efficacy over time [3], a poor tolerability and low 
compliance due to numerous adverse effects, including severe hypoglycaemia, weight 
gain, oedema, nausea and gastrointestinal derangements. Thus, new strategies were 
needed that allow a sustained glycaemic control and avoid hypoglycaemia and other 
side effects. 
After food ingestion, specialized neuroendocrine cells of the gastro-intestinal tract 
release peptides which act to improve glucose handling and energy homeostasis. 
Among these gut hormones are the incretins glucagon-like peptide (GLP)-1 and glucose-
dependent insulinotropic peptide (GIP) which increase meal-stimulated insulin release 
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by the pancreas, suppress glucagon secretion and improve glucose disposal. Recent 
advances in the understanding of the physiological functions of incretins have led to the 
emergence of a new class of oral anti-diabetic drugs which, by inhibiting the dipeptidyl 
peptidase (DPP)-4 enzyme, result in increased concentrations of the endogenous 
incretins GLP-1 and GIP, and consequently improve fasting and post-prandial 
hyperglycaemia. Several DPP-4 inhibitors have been developed, with five already 
approved in the USA, Europe and/or Japan (sitagliptin, vildagliptin, saxagliptin, alogliptin 
and linagliptin). These inhibitors display different chemical structures and 
pharmacodynamic/pharmacokinetic properties, but all are efficacious for managing 
diabetes and generally well-tolerated. They allow a reduction in HbA1c levels by 0.5 to 
1%, and have other beneficial actions on pancreatic β-cell function, blood pressure and 
lipid levels for instance. 
 
 
The ‘incretin effect’: physiological basis 
The term ‘incretin effect’ has been coined to describe stimulated insulin secretion after 
oral glucose ingestion compared to isoglycaemic parenteral or iv glucose administration 
[4]. Several peptides released by the intestine into the circulation in a nutrient-dependent 
manner account for this potentiation of post-prandial insulin release by the pancreas, 
and act as triggering signals for the control of appetite, intestinal nutrient absorption and 
ultimately in the maintenance of energy homeostasis [5]. GIP, for instance, is 
synthesized and released by entero-endocrine K cells present in the duodenum in 
response to nutrient (glucose or fat) ingestion and enhances glucose-stimulated insulin 
secretion [6;7]. The other incretin hormone GLP-1 derives from a pro-glucagon precursor 
peptide that gives rise also to GLP-2, oxyntomodulin and glicentin [8]. GLP-1 is secreted 
by L-cells mainly of the distal small intestine (ileum) and colon. Infusion of GLP-1 in the 
fasted state to mimic its post-prandial concentration increases insulin biosynthesis and 
release, and diminishes blood glucose [9;10]. Plasma levels of both peptides are low in 
the fasted state, rise within minutes after food ingestion and contribute to lower blood 
glucose by exerting potent glucose-dependent insulin stimulatory actions [7]. Indeed, 
GLP-1 and GIP stimulate β-cell insulin secretion [11;12]. In addition, the two incretins 
regulate pancreatic islet neogenesis, proliferation and survival in vitro [13] (Figure 1).  
Beside its insulinotropic effect, GLP-1 inhibits glucagon secretion by the pancreatic -
cells [14], resulting in a further decrease of hepatic glucose production in the post-
prandial state in subjects treated with GLP-1-receptor agonists or DPP-4 inhibitors. GLP-
 4 
1 also potentiates glucose disposal. Moreover, GLP-1 reduces food intake and gastric 
emptying through either direct effects on the gastrointestinal tract or indirect actions via 
the central nervous system [13], promoting satiety and improving weight maintenance. It 
is worth noting that, in humans, these effects are observed at supraphysiological 
concentrations, ie. only after administration of GLP-1 analogs. In addition, GLP-1 inhibits 
intestinal lipoprotein secretion and may lower post-prandial hyperlipidaemia, which is a 
cardiovascular risk factor. Finally, GLP-1 exerts potentially beneficial vascular and 
cardio-protective actions (see below). In support of the gluco-regulatory and insulin 
stimulatory actions of GLP-1, GLP-1 receptor-deficient mice display altered glucose 
tolerance and diminished glucose-stimulated insulin secretion, abnormal pancreatic islet 
number and size, but exhibit normal insulin sensitivity and glucagon secretion [15].  
As mentioned above, GIP promotes insulin secretion in response to glucose. However, it 
does not inhibit glucagon secretion nor does it modulate gastric emptying [13]. In 
addition, GIP increases fatty acid uptake and lipogenesis by adipocytes [16;17], 
promoting fat deposition. Accordingly, GIP-receptor-deficient mice have defective insulin 
secretion in response to oral glucose [18], but resist to the development of diet- or 
genetically-induced obesity and have improved insulin sensitivity [19]. GLP-1-receptor 
and GIP-receptor double knock-out mice are glucose intolerant as shown by the 
abnormal glucose excursion in oral glucose tolerance tests, and significantly lower 
glucose-stimulated insulin secretion [20].  
 
Several reports suggest that the incretin effect is reduced in type 2 diabetic patients [21] 
[22], although recent studies indicate that the reduction of insulin secretion is primarily 
due to an impairment in β-cell function after chronic hyperglycaemia rather than a 
primary defect in glucose-dependent GLP-1 and GIP action [23]. Defective post-prandial 
GLP-1 secretion in a mixed meal test has been observed in subjects with impaired 
glucose tolerance, albeit to a lesser extent compared to diabetic patients [22;24;25], 
although conflicting data have also been published [26]. In addition, the incretin effect 
and postprandial GLP-1 response is reduced with increasing obesity [27;28]. However, 
although its secretion is altered, GLP-1 action is mostly preserved in type 2 diabetic 
patients, fostering pharmaceutical efforts aimed to potentiate or prolong GLP-1 action. 
Unlike GLP-1, circulating levels of GIP are not diminished in type 2 diabetic patients [22], 
and GIP has reduced insulinotropic actions in type 2 diabetes, which contributes to the 
reduced incretin effect in diabetics thus making it a much less attractive therapeutic 
target.  
 5 
GLP-1 is secreted as GLP-1(7-36)-amide, the major circulating GLP-1 form, and GLP-
1(7-37). It is released within minutes of food ingestion and displays a short half-life (~1-2 
min) [29] because of its rapid degradation through the action of DPP-4 and its renal 
clearance. Only 25% of the secreted GLP-1 reaches the portal vein, and only 10 to 15% 
the general circulation (Figure 2). The half-life of administered GIP is 5 and 7 minutes in 
diabetic and non-diabetic subjects, respectively [30]. To counteract this rapid cleavage of 
native GLP-1 (and GIP), two therapeutic approaches have been developed: GLP-1 
mimetics resistant to the degradation by DPP-4 and inhibitors of DPP-4 (or gliptins).  
 
Physiological and preclinical studies to support the use of DPP-4 inhibitors in the 
control of glucose homeostasis 
DPP-4 exists as a cell surface membrane-bound peptidase which is expressed in many 
tissues including the gastro-intestinal tract, liver, kidney, the vascular epithelium and the 
exocrine pancreas, and conveys intracellular signals to transduction pathways. DPP-4 
also exists and exerts enzymatic activity in the plasma where it preferentially cleaves 
peptides with a proline or an alanine in position 2 of the N-terminus of the peptide. 
Hence, both GLP-1 and GIP, among others, are endogenous substrates for DPP-4. 
DPP-4 inhibition (by gliptins) or deletion studies in animal models have shed light on the 
role of this enzyme in glucose control. DPP-4-deficient mice show improved glucose 
tolerance, higher plasma GLP-1, GIP and insulin levels following an oral glucose 
gavage, reduced food intake and increased energy expenditure; they are resistant to 
diet-induced obesity and insulin resistance and to streptozotocin-induced diabetes 
[31;32]. Consistently, DPP-4 inhibition improved glucose tolerance, diminished 
hyperglycaemia and increased insulin secretion in diabetic Zucker rats [33-35] and 
increased hepatic and peripheral insulin sensitivity [36]. In vitro, vildagliptin-mediated 
DPP-4 inhibition increased insulin secretion by pancreatic islet cells [37]. Consistently, 
vildagliptin administration led to decreased weight gain and food intake, increased 
insulin levels and increased β-cell mass in carbohydrate-fed rats [38]. Sitagliptin 
treatment in vivo improved glucose homeostasis and pancreatic β-cell survival in 
diabetic streptozotocin-treated mice [39]. Sitagliptin has also been shown to increase β-
cell number and insulin content [40;41]. Treatment with a sitagliptin analog (des-fluoro-
sitagliptin) of diabetic ICR mice significantly reduced HbA1c and glucose levels, and 
decreased liver lipid accumulation while increasing pancreatic insulin content and 
enhancing glucose-stimulated insulin secretion [42]. 
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In vitro, many other peptides are degraded by DPP-4 including GLP-2, growth-hormone-
releasing hormone, pituitary adenylate cyclase activating polypeptide (PACAP) [43]. 
However, the hypoglycaemic action of DPP-4 inhibitors has been attributed mainly to 
increased GLP-1 and GIP levels. Indeed, administration of LAF237 (later renamed 
vildagliptin) or valine-pyrrolidide to inhibit DPP-4 activity led to a reduction of fasting 
glucose levels and ameliorated glucose tolerance in wild-type, but not in GLP-1-receptor 
and GIP-receptor double mutant mice, suggesting that both GLP1 and GIP signalling are 
necessary to the hypoglycaemic action of DPP-4 inhibitors [20]. In addition, 
administration of LAF237 to high-fat diet-fed mice improved glycaemic control in wild-
type, but not GLP-1R and GIPR double mutant mice [44]. 
 
Pharmacodynamic and pharmacokinetic properties of the different DPP-4 
inhibitors  
As mentioned above, several inhibitors are on the market or in trials (Table 1). They are 
all orally available and well absorbed (ie significant DPP-4 inhibition is observed as soon 
as 15 minutes after administration), and have high affinity for DPP-4. They all potently 
inhibit plasma DPP-4 to similar levels, but with different IC50 (ie the concentration 
needed to achieve 50% of inhibition) ranging from 1nM for linagliptin, 19 and 24nM for 
sitagliptin and alogliptin, to 50 and 62nM for saxagliptin and vildagliptin, respectively. 
Their half-life also is different, leading to different dosing amount and frequency as 
outlined below. 
 
Sitagliptin is well absorbed (~87%), and potently and selectively inhibits DPP-4. Its 
pharmacokinetic and pharmacodynamic properties have been determined in 
randomized, double-blind, placebo-controlled studies with single oral doses (1.5-600 mg) 
in healthy subjects [45]. Sitagliptin has an apparent terminal half-life ranging from 8 to 14 
hours. Single doses of sitagliptin markedly and dose-dependently inhibited plasma DPP-
4 activity, with >80% inhibition over the entire 24-hour period at 100 mg. PK-PD 
relationships using multiple oral doses of sitagliptin were also obtained in healthy 
volunteers [46] and showed similar plasma concentrations, Tmax (time to maximal 
plasma concentration), Cmax, and terminal half-life (11.8 to 14.4 hours) at day 1 (ie after 
a single dose) and day 10 (steady-state) of treatment. In this study, plasma DPP-4 
activity was inhibited by more than 80% over 24 hours at 50 mg and higher doses. GLP-
1 concentrations were increased by approximately 2-fold by sitagliptin. In obese, non-
diabetic subjects, sitagliptin 200 mg bid was well tolerated and led to approximately 90% 
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inhibition of plasma DPP-4 activity, increased GLP-1 levels by 2.7-fold, and decreased 
post-oral glucose tolerance test glucose excursion by 35% compared to placebo [47].  
Vildagliptin is also well (85%) and rapidly absorbed (within 1 to 2 hours) [48]. Vildagliptin 
is quickly cleared from plasma, with a half-life of 1.5 to 4.5 hrs, thus demanding higher 
dosing frequency (twice daily vs once daily for other gliptins). PD-PK relationships have 
been studied in a cross-over, placebo-controlled study in type 2 diabetic patients using 
doses ranging from 10 and 25 to 100mg twice a day, for 28 days [49]. More than 90% 
inhibition of DPP-4 activity was observed at all doses, and more than 80% 12 hrs post-
dosing [50]. 
Saxagliptin displays a good bioavailability (67%) and is also a potent selective long-
acting DPP-4 inhibitor administered usually at a dose of 5mg/day once a day [51]. As 
vildagliptin, it is cleared rapidly from the plasma with a ½ life of 2.5hrs, and between 3 
and 7 hours for its major 5-hydroxy saxagliptin metabolite (BMS-510849), also a 
reversible inhibitor of DPP-4 but 2-fold less potent than the parent molecule. However, it 
is administered once daily, based on the reasoning that saxagliptin, as vildagliptin, forms 
a covalent, yet reversible, complex with the enzyme, which has been suggested to 
confer an extended activity, whereas sitagliptin, alogliptin and linagliptin form non-
covalent bounds. 
The PK-PD relationship of various doses (25, 100 or 400 mg) of alogliptin  was studied 
in type 2 diabetic patients over 14 days [52]. A potent inhibition of plasma DPP-4 activity 
(82-97%) was observed at 24 hrs after administration of the last dose [53]. Alogliptin is 
usually used at 25 mg once a day.  
Linagliptin is generally used at a dose of 25 mg once a day. It inhibits DPP-4 in vitro with 
a lower IC50 ~ 1nM compared to other gliptins. Linagliptin has been administered to 
healthy volunteers at different doses (up to 600mg). It is well tolerated, with a low renal 
excretion and a terminal half-life around 180 hours [54]. Single doses of 2.5 mg and 5 
mg inhibited DPP-4 activity by 72.7% and 86.1%.  
 
Potency and duration of inhibition 
As outlined above, although some differences exist with regards to their chemical 
structures and pharmacodynamics-kinetics, when administred at therapeutic doses (from 
5 to 100 mg) and dosing frequencies (once/twice a day), they all potently inhibit plasma 
DPP-4 activity (measured ex vivo) by 70 to 90% at 24 hours post-dosing. Indeed, a 
single dose of sitagliptin (100mg) inhibited plasma DPP-4 activity by >80% over a 24-
hour period [46], while the same dose of vildagliptin inhibited by more than 80% DPP-4 
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activity 12 hrs post-dosing [50]. Similar results were obtained in healthy and type 2 
diabetic patients, with 25 mg alogliptin or 5 mg linagliptin, with more than 80 % inhibition 
over 24 hrs [53-55]. Thus, all DPP-4 inhibitors exert potent and sustained DPP-4 
inhibition at therapeutic dosing.  
 
Metabolism and excretion  
Sitagliptin is mainly (74%) eliminated unmodified via the kidney in a dosage-independent 
manner, and renal insufficiency may cause an increase in circulating levels [56;57]  
requiring different dosing in these patients. A single dose of 50 or 25 mg sitagliptin has 
been administered daily to type 2 diabetic patients with renal insufficiency for 54 weeks 
[58]. A reduction of HbA1c levels by 0.7% has been observed and adverse events were 
not increased. Sitagliptin gives rise through the action of hepatic CYP450 to 6 
metabolites, 3 being active [57]. As sitagliptin, alogliptin is mainly excreted unchanged in 
the urine [53]. In contrast, linagliptin is primarily excreted via the bile, and renal 
impairment has only a minor effect on linagliptin pharmacokinetics. Thus, there will be no 
need for adjusting the linagliptin dose in renally impaired patients with T2D [59]. By 
contrast, vildagliptin is mainly (> 50%) hydrolyzed by P450 cytochromes to one major 
pharmacologically inactive compound which is excreted in the urine. Hence, dose 
adjustment may apply in renal or hepatic insufficiency. Saxagliptin is metabolized in the 
liver via P450 cytochromes to an active compound which is also a competitive reversible 
DPP-4 inhibitor. Both this compound and the parent saxagliptin are cleared by the 
kidney. However, hepatic insufficiency does not seem to alter the pharmacokinetics of 
saxagliptin [60].  
 
Selectivity 
DPP-4 belongs to a large family of structurally related prolyl-peptidases which includes 
also DPP-8 and DPP-9. Lankas et al. have shown that DPP-8/9 inhibition in vivo in rats 
leads to alopecia, thrombocytopenia, reticulocytopenia, enlarged spleen, multiorgan 
histopathological changes, and mortality [61]. Non- or partial selectivity of DPP-4 
inhibitors could therefore be of clinical importance although a class effect is very unlikely 
because of the differences in the chemical structure of the different DPP-4 inhibitors. 
Hence, molecules thought to be specifically DPP-4-targeted may in fact inhibit other 
enzymes of this family and its selectivity should be carefully examined. Sitagliptin, 
alogliptin and linagliptin are highly selective of DPP-4, whereas vildagliptin appears less 
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selective. However, in mice and rats, chronic administration of vildagliptin at doses 
allowing DPP8/9 inhibition did not result in organ toxicity [62].  
 
 
DPP-4 inhibitors in clinical trials  
Although structurally different, all DPP-4 inhibitors efficiently lower fasting and post-
prandial hyperglycaemia and reduce HbA1c levels by 0.7 to 1% as shown in numerous 
phase II and phase III trials. They also improve β-cell function in short-term studies as 
attested by the HOMA-B index and the decreased pro-insulin/insulin ratio. 
Sitagliptin 
Sitagliptin has been evaluated in several phase III trials as monotherapy or combination 
therapy. As monotherapy, in a placebo-controlled, double-blind, 24 weeks study, 
sitagliptin 100mg and 200 mg led to a reduction in HbA1c (-0.79 and -0.94%, 
respectively) and fasting glucose (-17.1 mg/dl and -21.3 mg/dl, respectively) levels, and 
lower post-prandial glucose in a meal tolerance test [63]. A greater reduction of HbA1c 
was achieved in patients with baseline HbA1c>9% (placebo-subtracted reductions of -
1.52 and -1.50% for the 100- and 200-mg treatment groups, respectively). At 24 weeks, 
the percentage of patients achieving HbA1c<7% was 41% with 100mg and 45% with 
200mg vs 17% for placebo. In this study, sitagliptin also improved the HOMA-B index 
without clinically relevant hypoglycaemic episodes and with a small but significant weight 
loss compared to placebo. 
In a double-blind, randomized study, sitagliptin 100 mg/d alone or in combination with 
2g/d metformin during 24 weeks reduced HbA1c levels by 0.83% and 2.07% vs placebo, 
respectively, demonstrating an additive effect [64]. Adverse effects were similar to those 
with metformin alone. In another study, sitagliptin 100mg has been given in association 
with metformin vs metformin alone, for 24 weeks. Sitagliptin reduced HbA1c levels by an 
additional 0.65% [65]. Fasting blood glucose was also reduced by 25.4 mg/dl, HOMA-B 
was improved and body weight remained unchanged. A small but significant decrease in 
plasma cholesterol (total- and non-HDL-cholesterol) and triglycerides was also observed 
with sitagliptin 100mg but the between-group (placebo-subtracted) differences were not 
significant.  
Sitagliptin (100mg once daily) in association with pioglitazone 30 or 45mg/d was 
evaluated in a 24-week study. It reduced HbA1c levels by 0.85% (baseline 
HbA1c=8.1%), fasting blood glucose by 16.7mg/dl, and after 24 weeks 45% of the 
patients had HbA1c less than 7% vs only 23% taking pioglitazone alone [66]. 
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Sitagliptin was also evaluated for 52 weeks in a non-inferiority trial compared with a 
sulfonylurea (glipizide: 5 to 20 mg/d) in diabetic patients with inadequate control of 
HbA1c by metformin alone [67]. Sitagliptin was proven non-inferior on HbA1c (-0.67% at 
52w) and glucose levels, with significantly less hypoglyceamic episodes and a gradual 
decrease in body weight compared to glipizide. 
Similarly, in another study comparing the addition of sitagliptin or glipizide on on-going 
metformin therapy during 2 years, sitagliptin reduced HbA1c levels by -0.54% compared 
to -0.51% with glipizide and the percentage of patients with HbA1c levels <7% was 63% 
and 59%, respectively [68]. Sitagliptin was associated with weight loss (-1.6 kg) and a 
lower incidence of hypoglycemia.  
In a recent head-to-head comparison of sitagliptin vs liraglutide, a GLP-1 analog, in 
patients with inadequate glycaemic control on metformin (mean HbA1c 8.5% at 
baseline) [69], 100 mg sitagliptin for 26 weeks reduced HbA1c levels by 0.9%, whereas 
1.2mg and 1.8 mg liraglutide led to a significantly greater reduction (-1.24% and -1.50%, 
respectively). In addition, mean weight loss was greater with liraglutide compared to 
sitagliptin, whereas nausea was more common with liraglutide than with sitagliptin. 
 
Vildagliptin 
Used as a monotherapy for 24 weeks in a double-blind, placebo-controlled study in drug-
naïve diabetic patients, vildagliptin (50mg/d, 50mg twice a day, or 100mg qd) 
significantly reduced HbA1c by 0.5%, 0.7% and 0.9%, respectively, and reduced fasting 
glucose levels without change in body weight and the incidence of adverse events [70]. 
Vildagliptin 50mg once or twice daily in association with metformin for 24 weeks was 
administered to diabetic patients with baseline HbA1c levels ~ 8.4%. Vildagliptin 50 and 
100mg reduced HbA1c by -0.7 and -1.1%, respectively. Fasting (-14 and -31mg/dl) and 
post-prandial glucose (-34 and -41mg/dl) was also decreased [71]. In association with 
pioglitazone (45 mg daily) in diabetic patients with inadequate glycaemic control on prior 
monotherapy, vildagliptin (50mg once or twice daily for 24 weeks) resulted in a decrease 
of HbA1c levels by -0.8 and -1%, fasting glucose levels by -14.4 and -19.8 mg/dl, and 
reduced post-prandial glucose [72]. In both studies, no change in body weight was 
observed, and vildagliptin was well tolerated (the incidence of hypoglycemia and other 
adverse effects was not increased). 
Vildagliptin 50 mg twice daily vs sulphonylurea (glimepiride) was administered for 52 
weeks in patients receiving metformin and displaying inadequate glycaemic control [73]. 
Vildagliptin treatment reduced HbA1c and fasting glucose levels by -0.44% and -18mg/dl 
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and was non-inferior compared to glimepiride (mean dose: 4.5 mg/d). The incidence of 
hypoglycemic episodes was significantly reduced in the vildagliptin arm compared to the 
sulphonylurea treated group. 
 
Linagliptin 
Linagliptin was also evaluated as monotherapy or add-on therapy and has shown 
clinically meaningful improvement of glycaemic control in type 2 diabetes. Linagliptin 
was given as monotherapy, 5mg once daily achieving a concentration >6.4nM leading to 
a median >82% DPP-4 inhibition, during 24 weeks in drug-naïve patients or patients 
receiving oral antidiabetic agents (other than TZDs) prior to a 6-week wash-out period 
[74]. In this multicenter, randomized, placebo-controlled, phase III trial, linagliptin 
improved glycaemic control (HbA1c -0.69 % from baseline, -1.01% in the patients with a 
baseline HbA1c > 9%). The percentage of patients who achieved HbA1c<7% was 25.2% 
with linagliptin vs 11.6% in the placebo group. Fasting and 2h post-prandial glucose 
were significantly reduced in the linagliptin arm compared to placebo (-1.3 mM [23mg/dl] 
vs placebo and -3.2 mM [58mg/dl] vs placebo, respectively). Glucose excursion after a 
test meal was also significantly reduced. In addition, an enhancement of β-cell function 
was observed (differences were seen in the proinsulin/insulin ratio, the HOMA-B index 
and the disposition index). Linagliptin was well tolerated and the safety profile was 
comparable to the placebo group (no drug-related serious event) and hypoglycaemic 
episodes were not increased compared to the placebo group. There was no increase of 
body weight. 
The efficacy and safety of linagliptin (5 mg once daily) in combination with metformin 
during 24 weeks was also evaluated in type 2 diabetic patients in a randomized, 
placebo-controlled, double-blind, multi-center study [75]. Linagliptin led to a significant 
reduction in HbA1c (-0.5% from baseline) and fasting and post-prandial glucose. The 
risk of hypoglycaemic episode was not increased and linagliptin was weight neutral. As 
mentioned above, linagliptin is mainly excreted unchanged in the urine and can thus be 
used in patients with severe renal insufficiency [76].  
Linagliptin (5mg once daily) has proven non-inferior to sitagliptin (100 mg once daily) in 
T2D patients in a randomized, double-blind, placebo-controlled study assessing fasting 
and 24-hrs plasma glucose changes from baseline as well as plasma GLP-1 AUC (0-2h) 
and glucose AUC (0-3h) from baseline (clinicaltrials.gov, NCT00716092).  
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Alogliptin 
Clinical evidence also supports the efficacy of alogliptin. Used as a monotherapy in a 
double-blind placebo-controlled study, alogliptin 12.5 and 25mg once daily resulted in a 
significant reduction of HbA1c by 0.6%, and was weight neutral [77].  
Several studies showed that alogliptin in combination with other oral antidiabetic agents 
also improves glycaemic control. In association with metformin in type 2 diabetic patients 
with baseline HbA1c from 7 to 10%, 12.5 and 25mg alogliptin once daily for 26 weeks 
significantly reduced HbA1c and fasting blood glucose by an additional -0.6% and -
17mg/dL, respectively, over placebo [78]. 
In a randomized, double-blind trial, the administration of 12.5 and 25mg alogliptin for 26 
weeks in patients inadequately controlled by the sulphonylurea glyburide (mean baseline 
HbA1c 8.1%) led to a further reduction of HbA1c levels by 0.53 and 0.39%, and fasting 
glucose by -8.4 and -4.7mg/dL [79]. 
Used with insulin, alogliptin 12.5 and 25 mg for 26 weeks improved glycaemic control as 
Hb1Ac was decreased by 0.63% and 0.71%, respectively [80]. 
 
Saxagliptin 
Saxagliptin also improves glycemic control and is well-tolerated. As monotherapy, 
saxagliptin 2.5, 5, 10, 20 and 40 mg once a day reduced HbA1c levels by 0.45-0.63% vs 
placebo and was neutral on body weight [81;82]. In another study, saxagliptin 2.5, 5 and 
20mg daily for 24 weeks led to a reduction of HbA1c of 0.43%, 0.46% and 0.54%, 
respectively [81;82].  
Saxagliptin vs placebo added to either metformin, a TZD (rosiglitazone or pioglitazone) 
or glyburide for 24 weeks resulted in significant reductions in HbA1c (-0.69%, -0.94% 
and -0.64% at 5mg) [83-85]. Fasting glucose was also reduced. The incidence of 
hypoglycaemia and other adverse events was not different from placebo in either three 
studies. In a randomized, double-blind, placebo-controlled study, saxagliptin was given 
for 12 weeks at 2.5 mg once daily to patients with renal impairment and inadequately 
controlled type 2 diabetes (baseline HbA1c 7 to 11%) [86]. In this study, saxagliptin 
lowered HbA1c by 0.42% over placebo, and achieved greater HbA1c reduction than 
placebo in a subset of patients with moderate (-0.64% vs -0.05%) and severe (-0.95 vs -
0.50%) renal insufficiency. 
Saxagliptin 5 mg once daily and sitagliptin 100 mg once daily were compared in a head 
to head, 18-week, double-blind, non-inferiority trial in patients on metformin with 
inadequately controlled glycaemia [87]). The mean changes in HbA1c in the saxagliptin 
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and sitagliptin groups were -0.52 and -0.62%, respectively. There was no between-group 
difference, demonstrating non-inferiority of saxagliptin vs sitagliptin. Both treatments 
were equally tolerated.  
 
Adverse effects 
DPP-4 inhibitors are generally well-tolerated, and no increase in adverse events was 
noted compared to placebo or other comparatives, but again slight differences may exist 
between the different molecules of this class. DPP-4 is also present on the cell 
membrane of T lymphocytes known as CD26. In these cells, it acts by activating 
intracellular signalling pathways to simulate T cell proliferation. In pre-clinical models, 
DPP-4-deficiency results in modest abnormalities in immune response, decreased CD4+ 
T cell number, and reduced production of interleukin (IL)-4 while IL-10 was increased 
[88;89]. However, the peptidase activity of DPP-4 has not been associated to immune 
function. DPP-4 inhibitors did not affect immune function in rats and dogs [61]. The effect 
of sitagliptin was also examined in type 1 diabetes where it was shown to reduce the 
effect of autoimmunity on islet graft survival  linked to decreased T cell migration [90]. In 
the same line, alogliptin was shown to suppress LPS-induced TLR-4 signalling [91]. 
Saxagliptin administration led also to a modest reduction in lymphocyte count within the 
normal range [81]. DPP-4 inhibition may also affect human progenitor cell and 
hematopoietic stem cell migration [92]. To date, no adverse events related to 
immunological effects have been reported in humans but additional long-term trials are 
needed before to conclude on their safety profile with regards to immunological issues.  
Some infections of the urinary tract and of the upper respiratory tract (nasopharyngitis) 
were reported to be slightly increased with the use of sitagliptin and vildagliptin, but this 
was not confirmed in later studies [93]. 
 
As mentioned above, several hormones and peptides harbouring an alanine or a proline 
at position 2 are degraded by DPP-4 in in vitro systems [43], although only a few were 
identified as endogenous physiological substrates. These include the chemokines 
SDF1α and β, GLP-2 and the vasodilatator substance P. DPP-4 inhibitors are 
considered safe therapies, and no serious adverse events have been reported. 
Nevertheless as with all new drug classes, long-term follow up is required to evaluate 
potential safety issues. 
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DPP4 inhibitors and cardiovascular risk 
Numerous studies have evidenced a role for GLP-1 in the cardiovascular system. On the 
one hand, continuous IV administration of GLP-1 in cardiac insufficiency and myocardial 
infarction improves cardiac function by increasing left ventricular ejection fraction [94]. 
Administration of the DPP-4-resistant GLP-1 analog exendin-4 to apoE-deficient mice, 
which spontaneously develop atherosclerosis, diminished atherosclerotic lesion size and 
monocyte/macrophage recruitment to the vascular wall independent of changes in 
plasma lipid levels or glucose tolerance [95]. On the other hand, deletion of the GLP-1 
receptor in mice results in increased left ventricular diastolic pressure, decreased left 
ventricle (LV) contractility and increased LV thickness [96]. In humans, GLP-1 
administration increased left ventricular ejection fraction and improved the resistance to 
exercise in diabetic and non-diabetic patients with cardiac insufficiency [97], suggestive 
of a potential cardioprotective effect of GLP-1. In the same line, GLP-1 infusion lowered 
arrhythmia in patients with coronary artery bypass grafting [98], while retrospective data 
base analysis suggested that administration of exenatide may diminish the relative risk 
of CVD in type 2 diabetic patients [99]. By contrast, 48-h GLP-1 infusion had no major 
cardio-vascular effects in patients with congestive heart failure [100].   
A recent study conducted in 14 patients with coronary artery disease indicated that a 
single administration of 100mg sitagliptin increases ejection fraction and improves 
contractile function on ischemic segments [101]. It is noteworthy that not all effects are 
necessary dependent on DPP-4 as sitagliptin was shown to slightly improve recovery 
from ischemia-reperfusion in isolated hearts from DPP-4 deficient as well as wild-type 
mice [102]. In addition, sitagliptin was shown to reduce diastolic blood pressure and 
heart rate with a similar extent than liraglutide [69]. A meta-analysis has suggested a 
potential reduction of cardiovascular events with saxagliptin [103]. A meta-analysis of 29 
placebo-controlled and 11 active comparator, randomized trials with DPP-4 inhibitors 
(sitagliptin and vildagliptin) also found a reduction in the risk of cardio-vascular events 
(odd ratio=0.76 vs control groups) [104]. Thus, evidence so far indicates that gliptins do 
not adversely affect the risk of cardiovascular events and animal studies suggest 
potential protective effects. However, prospective trials investigating the effects of DPP-4 
inhibitors on cardiovascular outcomes are ongoing (Table 2) and the results eagerly 
awaited. TECOS  (clinicaltrials.gov, NCT00790205) is a randomized, placebo-controlled 
clinical trial designed to assess the cardiovascular outcome of long term (up to 5 years) 
treatment with sitagliptin in an estimated number of 14,000 patients with T2D (HbA1c 
between 6.5% and 8.0%) and a history of cardiovascular disease. Primary end-points 
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are defined as CV-related death, nonfatal myocardial infarction (MI), nonfatal stroke, or 
unstable angina requiring hospitalization ([105] and http://clinicaltrials.gov/). The 
cardiovascular safety of linagliptin will be tested in a randomised, double-blind study in 
6,000 patients with T2D and at elevated cardiovascular risk. Linagliptin will be compared 
against glimepiride (CAROLINA study)[106]. The primary outcome is defined as the time 
to the first occurence of any of the following events: CV death, non-fatal MI, non-fatal 
stroke and hospitalisation for unstable angina pectoris (clinicaltrials.gov, NCT01243424). 
SAVOR-TIMI 53 (NCT01107886) is a randomised, double-blind, placebo-controlled 
phase IV trial evaluating the effect of saxagliptin on the incidence of cardiovascular 
death, non-fatal MI or non-fatal ischaemic stroke in 16,500 patients with T2D. Finally, 
EXAMINE (NCT00968708) is a randomized, double-blind, placebo-controlled study that 
will evaluate cardiovascular outcomes upon treatment with alogliptin in subjects with 
T2D and acute coronary syndrome (acute MI or unstable angina)[107]. In addition, the 
effects of 52 weeks vildagliptin treatment on LV function will be tested in patients with 
T2D and congestive heart failure (NCT 00894868) in a randomized, double-blind, 
placebo-controlled phase IV trial (estimated completion date jan 2013). 
 
Conclusion 
DPP-4 inhibitors are a novel class of orally available molecules for the treatment of type 
2 diabetes. Although structurally different, they share a common mechanism of action by 
extending the half-life of endogenous GLP-1 thus prolonging its actions, they potently 
reduce blood glucose levels and lower HbA1c by up to 1%. They are generally well 
tolerated and safe. Because GLP-1 is secreted in a glucose-dependent manner, DPP-4 
inhibitors, which prolong its half-life, are not associated with an increased risk of 
hypoglycaemic episodes.  
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Table 1: Gliptins in development and licensed. 
 
Compound Company Status 
Sitagliptin (MK-0431) Merck Launched 2006 
Vildagliptin (LAF-237) Novartis Launched 2008 
Saxagliptin Bristol-Myers Squibb and 
Astra Zeneca 
Launched 2009; recently 
approved in Europe for the 
treatment of T2D with 
moderate to severe renal 
insufficiency or mild hepatic 
insufficiency (2011) 
Alogliptin (SYR-322) Takeda Launched in Japan  
Linagliptin (BI-1356) Boehringer-Ingelheim Launched 
Dutogliptin (PHX1149) Phenomix Pharmaceuticals Phase III 
Teneligliptin (MP-513) Mitsubishi Tanabe Pharma 
Corp 
Phase III, filled application 
for Japan (sept 2011) 
SYR472 Takeda Phase III 
KRP104 Kyorin PhaseII 
LC15-0444 LG Life Sciences Phase II 
Melogliptin (GRC8200) Glenmark Phase II 
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Table 2: Ongoing trials investigating the effects of DPP-4 inhibitors on cardiovascular 
disease outcomes 
Trial Intervention 
and duration 
Inclusion and 
estimated nb of 
patients 
Primary endpoint Estimated 
completion 
date / 
Status 
TECOS  
(Phase III) 
NCT00790205
* 
Sitagliptin vs 
placebo 
(Up to 5 
years) 
14,000 subjects with 
T2D and inadequate 
glycemic control and 
history of CVD, >50y 
CV-related death, 
nonfatal MI, nonfatal 
stroke, or unstable 
angina requiring 
hospitalization 
Dec 2014/ 
 Recruiting 
CAROLINA 
(Phase III) 
NCT01243424 
 
Linagliptin vs 
glimepiride 
400 weeks 
(7.5 years) 
6,000 T2D patients CV death, non-fatal MI, 
non-fatal stroke and 
hospitalisation for 
unstable angina 
pectoris at Week 400 
(or FinalVisit) 
Sept 2018/ 
 Recruiting  
SAVOR-TIMI 
53 (Phase IV) 
NCT01107886 
Saxagliptin 
vs placebo  
(5 years) 
16,500 T2D patients CV death, non-fatal MI 
or non-fatal ischaemic 
stroke 
April 2014/ 
 Recruiting  
EXAMINE  
(Phase III) 
NCT00968708 
Alogliptin vs 
placebo  
(4.7 years) 
5,400 T2D patients 
with acute coronary 
syndrome 
CV, nonfatal MI and 
nonfatal stroke 
dec 2014/ 
 Recruiting 
* clinicaltrials.gov identifier 
 
Legends to figures 
Figure 1: Physiological actions of GLP-1 in different organs/tissues  
Upon meal ingestion, GLP-1 is secreted by the intestine. GLP-1 enhances glucose-
stimulated insulin secretion (‘incretin effect’), diminishes glucagon production and 
hepatic glucose production, and increases pancreatic β-cell proliferation and survival. 
Additional actions have been described including gastric emptying, reduction of appetite 
and cardioprotective actions, among others. 
 
Figure 2: GLP-1 is rapidly degraded by dipeptidyl-peptidase (DPP-4)  
GLP-1 has a short half-life (1-2 min) because of rapid proteolytic degradation by DPP-4 
(and renal elimination). DPP-4 inhibitors thus increase its half-life which results in 
prolongation of its biological actions. 
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Figure 3: Structure of the different approved DPP-4 inhibitors. 
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